Holen Sie sich die Stockscreener-App
29.98
0.62%
0.185
Schlusskurs vom Vortag:
$29.80
Offen:
$30.02
24-Stunden-Volumen:
280.77K
Relative Volume:
0.56
Marktkapitalisierung:
$1.85B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.84M
KGV:
-6.5613
EPS:
-4.57
Netto-Cashflow:
$-6.73M
1W Leistung:
+15.28%
1M Leistung:
+42.72%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$29.05
$30.52
1-Wochen-Bereich:
$25.76
$30.75
52-Wochen-Spanne:
$16.50
$30.75
Damora Therapeutics Inc Stock (DMRA) Company Profile
Firmenname
Damora Therapeutics Inc
Sektor
Branche
Telefon
(781) 281-9020
Adresse
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
29.98 | 1.85B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2026-02-17 | Eingeleitet | UBS | Buy |
| 2026-01-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Price to sales forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora awards 453,500 stock options to nine new hires - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Index - marketscreener.com
Damora Therapeutics (DMRA) Is Up 6.2% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Damora Therapeutics, Inc. Actuals & Estimates (NASDAQ:DMRA) - TradingView
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Value Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Value Benchmark - marketscreener.com
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts - Quiver Quantitative
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
DMRA Forecast — Price Target — Prediction for 2027 - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Form 144 Damora Therapeutics For: 22 June By Investing.com - Investing.com India
DMRA (NASDAQ: DMRA) Form 144 lists option-based sales to Maxim Group - Stock Titan
Damora Therapeutics (DMRA) Slips 0.89% as Stock Holds Above Key SupportOn Balance Volume - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Damora Therapeutics Announces Results of 2026 Annual Meeting - TipRanks
DMRA: All proposals passed, including director elections and auditor ratification, with strong shareholder support - TradingView
Damora Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Costs WeighEBITDA Margin Trends - newsline.com
DMRA Reiterates by Wedbush -- Price Target Maintained at $35 - GuruFocus
DMRA Initiated Coverage by HC Wainwright & Co. -- Price Target S - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
TD Cowen initiates Damora Therapeutics stock rating at Buy - Investing.com UK
Finanzdaten der Damora Therapeutics Inc-Aktie (DMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Damora Therapeutics Inc-Aktie (DMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bruno Julianne | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
129,000 |
0 |
137,032 |
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):